Announcement
Pemberton Asset Management to support Fremman Capital’s acquisition of Amethyst Radiotherapy
Pemberton is pleased to be supporting Fremman Capital in their strategic investment in Amethyst Radiotherapy.
Amethyst is a leading radiotherapy and cancer care provider with facilities across Europe including in France, Poland, Romania, the UK, Italy and Austria.
Amethyst has built a strong reputation among both the medical community (including circa one hundred doctors working in its centres) and its patients, supported by a team of over 500 highly skilled professionals. Its modern, well-invested infrastructure includes around 40 linear accelerators, the core technology used to deliver the most innovative radiotherapy treatments, positioning the Group as one of the largest radiotherapy providers in Europe.
This transaction will allow Amethyst to accelerate the expansion of their network, broadening access to high quality cancer treatment for patients across the continent.
We are delighted to support Fremman’s acquisition of Amethyst, adding another high-quality healthcare provider to the Pemberton portfolio, backed by a top-tier sector investor. We look forward to supporting Fremman and management as they grow the business and increase access to critical radiotherapy and cancer care services across Europe.
– Richard Meehan, Managing Director and Co-Head of Origination, UK
We are very pleased with the Pemberton team’s understanding of the sector, commercial flexibility and speed of execution. We look forward to working together further as we build Amethyst into a pan-European champion in radiotherapy.
– Edward Chandler, Fremman Capital
